As previously stated, T-DM1 seems to be active in PIK3CA mutant BC; however, there is evidence that activation of the PI3K pathway may lead to acquired resistance to T-DM1 [74], as for trastuzumab, and its inhibition could restore sensitivity to this drug. Here, PIK3CB is linked to breast cancer.